CORRELATION OF THE SEVERITY OF CHRONIC KIDNEY DISEASE WITH CRP
Main Article Content
Keywords
.
Abstract
Background: Chronic kidney disease (CKD) is marked by kidney damage or a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 for at least three months, regardless of the underlying etiology. When a variety of renal problems are present, albuminuria defined as an albumin-to-creatinine ratio >30 mg/g in two out of three spot urine samples can serve to determine kidney failure. The three most typical CKD causes are glomerulonephritis, diabetes mellitus and hypertension. One in three persons with diabetes and one in five adults with hypertension both have CKD.[6] The etiology of chronic kidney disease also known as chronic kidney disease of undetermined etiology (CKDu), is uncertain in some cases. C-polymer, a polysaccharide present on the cell walls of pneumococcus was initially found to interact with a component in the serum of individuals undergoing acute inflammation, hence the name CRP. CRP is mostly utilized as an indicator of inflammation. There are only a few known conditions that prevent the formation of CRP, other from liver failure. The interferon alpha-induced suppression of CRP generation from liver cells may account for the relatively low levels of CRP observed during viral infections compared to bacterial infections.
Objective: The aim of the study was to assess the CRP in CKD and study the correlation between eGFR (which is a marker of severity of CKD) and CRP in CKD.
Materials and Methods: The present study was observational study. The study was conducted over a period of six months on 180 patients. Blood samples were obtained in Becton Dickinson's commercially available red capped tubes vacutainers (BD). After that, blood samples were left undisturbed at room temperature for 15-30 minutes to coagulate. For 5 minutes, the tubes were centrifuged at 3000 rpm. After centrifugation, the sample solution (serum) was transferred to a fresh polypropylene tube with a Pasteur pipette. Serum creatinine was done on fully automated SYSMEX BX-3010 and CRP were done on fully auto-analyzer NANOLAB 200.
Results: Our results show that mean and standard deviation of CRP with p value between males and females in the different stages of chronic kidney disease which shows a statistically significant difference in stage II (p=0.0286).
Conclusion: The present study highlights the progressive increase in CRP levels as CKD advances through its stages. This finding shows the increase in CRP levels as CKD progresses through its stages, particularly evident in Stage II in the present study underscores the importance of addressing inflammation in CKD management.
References
2. Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 12(1), 7-11.
3. Wanner, C., & Tonelli, M. (2014). KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international, 85(6), 1303-1309.
4. Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs,F. R. (2016). Global prevalence of chronic kidney disease–a systematic review and meta- analysis. PloS one, 11(7), e0158765.
5. Mohanty, N. K., Sahoo, K. C., Pati, S., Sahu, A. K., & Mohanty, R. (2020). Prevalence of chronic kidney disease in Cuttack district of Odisha, India. International Journal of Environmental Research and Public Health, 17(2), 456.
6. Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., ... & Boufous, S. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The lancet, 388(10053), 15451602.
7. Chaity, B. S. (2022). Treatment and prevention of chronic kidney disease.
8. Wesseling, C., Crowe, J., Hogstedt, C., Jakobsson, K., Lucas, R., & Wegman, D. H. (2013). The epidemic of chronic kidney disease of unknown etiology in Mesoamerica: a call for interdisciplinary research and action. American journal of public health, 103(11), 1927-1930.
9. Yousif, E. A., Ahmed, S. M. S., Alsadig, S. M., Elmukashfi, S. T. A., & Falih, R. E. (2019). Estimation of Salivary Creatinine and Urea as alternative to Plasma Creatinine and Urea in Sudanese Patients with Chronic Kidney Disease in Khartoum State-Sudan. Int. J. Curr. Res. Med. Sci, 5(9), 8-14.
10. Kalantar-Zadeh, K., Lockwood, M. B., Rhee, C. M., Tantisattamo, E., Andreoli,
S., Balducci, A., ... & Li, P. K. T. (2022). Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nature Reviews Nephrology, 18(3), 185-198.
11. Go, A. S., Chertow, G. M., & Fan, D. (2005). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Journal of Vascular Surgery, 41(1), 177.
12. Natale, P., Ruospo, M., Saglimbene, V. M., Palmer, S. C., & Strippoli, G. F. (2019). Interventions for improving sleep quality in people with chronic kidney disease. Cochrane Database of Systematic Reviews, (5).
13. Ladhani, M., Craig, J. C., Irving, M., Clayton, P. A., & Wong, G. (2017). Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 32(3), 439-449.
14. Mishra, R. K., Yang, W., Roy, J., Anderson, A. H., Bansal, N., Chen, J., ... & Shlipak, M. G. (2015). Kansas City Cardiomyopathy Questionnaire score is associated with incident heart failure hospitalization in patients with chronic kidney disease without previously diagnosed heart failure: chronic renal insufficiency cohort study. Circulation: Heart Failure, 8(4), 702-708.
15. Bansal, N., McCulloch, C. E., Rahman, M., Kusek, J. W., Anderson, A. H., Xie, D., ... & Hsu, C. Y. (2015). Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension, 65(1), 93-100.
16. Johnson, D. (2011). Chapter 4: CKD Screening and Management: Overview. Daugirdas, John. Handbook of Chronic Kidney Disease Management. Lippincott Williams and Wilkins, 32-43.
17. Patel, S. S., Molnar, M. Z., Tayek, J. A., Ix, J. H., Noori, N., Benner, D., ... & Kalantar-Zadeh, K. (2013). Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. Journal of cachexia, sarcopenia and muscle, 4, 19-29.
18. Myers, G. L., Miller, W. G., Coresh, J., Fleming, J., Greenberg, N., Greene, T., ... & National Kidney Disease Education Program Laboratory Working Group. (2006). Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical chemistry, 52(1), 5-18.
19. Drawz, P., & Rahman, M. (2015). Chronic kidney disease. Annals of internal medicine, 162(11), ITC1-ITC16.
20. El Nahas, A. M., & Bello, A. K. (2005). Chronic kidney disease: the global challenge. The lancet, 365(9456), 331-340.
21. Levey, A. S., Eckardt, K. U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., ... & Eknoyan, G. (2005). Definition and classification of chronic kidney disease: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney international, 67(6), 2089-2100.
22. Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., ... & Yang, C. W. (2013). Chronic kidney disease: global dimension and perspectives. The Lancet, 382(9888), 260-272.
23. Charles, C., & Ferris, A. H. (2020). Chronic kidney disease. Primary Care: Clinics in Office Practice, 47(4), 585-595.
24. Lv, J. C., & Zhang, L. X. (2019). Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies, 3-15.
25. Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., ... & Yang, C. W. (2013). Chronic kidney disease: global dimension and perspectives. The Lancet, 382(9888), 260-272.
26. Nacak, H., van Diepen, M., Qureshi, A. R., Carrero, J. J., Stijnen, T., Dekker, F. W., & Evans, M. (2015). Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrology Dialysis Transplantation, 30(12), 2039-2045.
27. Ye, M., Hu, K., Jin, J., Wu, D., Hu, P., & He, Q. (2018). The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study. BMC nephrology, 19, 1-10.
28. Xia, X., Luo, Q., Li, B., Lin, Z., Yu, X., & Huang, F. (2016). Serum uric acid and mortality in chronic kidney disease: a systematic review and metaanalysis. Metabolism, 65(9), 1326-1341.
29. Uludag, K., Boz, G., Arikan, T., & Gunal, A. I. (2022). Temporal evolution of Creactive protein levels and its association with the incident hospitalization risk among individuals with stage 3–4 chronic kidney disease. International Urology and Nephrology, 54(3), 609-617.
30. Jeena, J., Manhas, S., Prasad, R., Prasad, S., & Gupta, R. (2022). Direct Relationship Between Uric Acid and C-Reactive Protein and Its Implication in the Chronic Kidney Disease. Indian Journal of Clinical Biochemistry, 37(3), 365-369.
31. Miao, L., Min, Y., Qi, B., Zhu, C. M., Chen, J. H., Deng, G. X., ... & Li, R. S. (2021). Causal effect between total cholesterol and HDL cholesterol as risk factors for chronic kidney disease: a mendelian randomization study. BMC nephrology, 22, 1-9.
32. Zhang, L., Yuan, Z., Chen, W., Chen, S., Liu, X., Liang, Y., ... & Zou, H. (2014). Serum lipid profiles, lipid ratios and chronic kidney disease in a Chinese population. International Journal of Environmental Research and Public Health, 11(8), 7622-7635.
33. Arnold, R., Issar, T., Krishnan, A. V., & Pussell, B. A. (2016). Neurological complications in chronic kidney disease. JRSM cardiovascular disease, 5, 2048004016677687.
34. Cravedi, P., & Remuzzi, G. (2013). Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. British journal of clinical pharmacology, 76(4), 516-523.
35. Nehus, E. (2018). Obesity and chronic kidney disease. Current opinion in pediatrics, 30(2), 241-246.
36. Olsen, E., & van Galen, G. (2022). Chronic renal failure-causes, clinical findings, treatments and prognosis. Veterinary Clinics: Equine Practice, 38(1), 25-46.
37. Kazancioglu, R. (2013). Risk factors for chronic kidney disease: an update. Kidney international supplements, 3(4), 368-371.
38. Zhang, L., Zhang, P., Wang, F., Zuo, L., Zhou, Y., Shi, Y., ... & Wang, H. (2008). Prevalence and factors associated with CKD: a population study from Beijing. American Journal of Kidney Diseases, 51(3), 373-384.
39. Nivedita, A. K., Sinha, A., Mitra, J. K., & Sinha, R. (2021). Uric acid levels in chronic kidney disease-a hospital based cross-sectional study in RIMS, Ranchi, Jharkhand. International Journal of Research in Medical Sciences, 9(2), 569.
40. Kugler, E., Cohen, E., Goldberg, E., Nardi, Y., Levi, A., Krause, I., ... & Krause, I. (2015). C reactive protein and long-term risk for chronic kidney disease: a historical prospective study. Journal of nephrology, 28, 321-327.
41. Menon, V., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Marcovina, S. M., & Sarnak, M. J. (2003). Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. American Journal of Kidney Diseases, 42(1), 44-52.
42. Son, M., Seo, J., & Yang, S. (2020). Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. PLoS One, 15(2), e0228684.
43. Nakano, T., Tanaka, S., Tsuruya, K., & Kitazono, T. (2021). Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study. Clinical and Experimental Nephrology, 25, 385-393.
44. Lamprea-Montealegre, J. A., Shlipak, M. G., & Estrella, M. M. (2021). Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention. Heart, 107(16), 1282-1288.
45. Sonoda, H., Takase, H., Dohi, Y., & Kimura, G. (2011). Uric acid levels predict future development of chronic kidney disease. American journal of nephrology, 33(4), 352-357.
46. Mora-Gutiérrez, J. M., MF, S. R., & Bilbao, C. (2016). Chronic kidney disease in the elderly patient. Revista Espanola de Geriatria y Gerontologia, 52(3), 152158.
47. Streja, E., Norris, K. C., Budoff, M. J., Hashemi, L., Akbilgic, O., & KalantarZadeh, K. (2021). The quest for cardiovascular disease risk prediction models in patients with nondialysis chronic kidney disease. Current opinion in nephrology and hypertension, 30(1), 38-46.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rajinderjit Singh Ahi
Department of biochemistry, Adesh Institute of Medical Sciences & Research, Bathinda
Varun Khanna
Tutor Biochemistry, CMC Ludhiana, Punjab